Pharmaceutical compositions comprising 4-(6BR,10AS)-3-methyl-2,3,6B,9,10,10A-hexahydro-1h, 7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one and methods of treating conditions of the central nervous system
The invention relates to pharmaceutical compositions comprising compounds of Formula Q: wherein W is N(H)—, or —N(CH 3 )—, and Y is —C(═O)— or —O—, in free base or pharmaceutically acceptable salt form, and methods of use in the treatment of diseases involving 5-HT 2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D 2 receptor pathway, and methods of treating conditions of the central nervous system therewith.
1. A pharmaceutical composition comprising:
(i) a compound of Formula Q:
wherein:
W is —N(H)— or —N(CH 3 )—; and
Y is —C(═O)— or —O—;
in free base or pharmaceutically acceptable salt form;
(ii) a polymeric matrix; and
(iii) a vehicle comprising a viscosity enhancing agent.
2. The pharmaceutical composition according to claim 1 , wherein the compound of Formula Q is either dissolved in the polymeric matrix or dispersed in the polymeric matrix.
3. The pharmaceutical composition according to claim 1 , wherein the polymeric matrix comprises one or more polymers selected from the group consisting of poly(lactic acid), poly(glycolic acid), poly(citric acid), poly(malic acid), poly(beta-hydroxybutyric acid), lactic acid-glycolic acid copolymer, poly(lactide-co-glycolide), 2-hydroxybutyric acid-glycolic acid copolymer, poly(lactic acid)-poly(ethylene glycol) copolymer, poly(glycolic acid)-poly(ethylene glycol) copolymer, a poly(alkyl alpha-cyanoacrylate), a poly(alkylene oxalate), a poly(orthoester), a polycarbonate, a poly(orthocarbonate), a polyamino acid, a hyaluronic acid ester, a poly(aliphatic carboxylic acid), a copolyoxalate, a polycaprolactone, a polydioxanone, a poly(acetal), a poly(lactic acid-caprolactone), and a poly(glycolic acid-caprolactone).
4. The pharmaceutical composition according to claim 3 , wherein the polymeric matrix comprises a poly(D,L-lactide-co-glycolide) polymer.
5. The pharmaceutical composition according to claim 4 , wherein the polymeric matrix is a microspheric polymeric matrix comprising a biodegradable poly(D,L-lactide-co-glycolide) polymer.
6. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is formulated as a sustained-release and/or delayed release injectable composition.
7. The pharmaceutical composition according to claim 1 , wherein the viscosity enhancing agent is a sodium carboxymethylcellulose.
8. The pharmaceutical composition according to claim 1 , wherein the vehicle further comprises a pharmaceutically acceptable diluent or carrier.
9. The pharmaceutical composition according to claim 1 , wherein:
W is —N(CH 3 )—; and
Y is —C(═O)—.
10. The pharmaceutical composition according to claim 9 , wherein the compound of Formula Q is in pharmaceutically acceptable salt form.
11. The pharmaceutical composition according to claim 10 , wherein the pharmaceutically acceptable salt form is a toluenesulfonic acid addition salt form.
12. The pharmaceutical composition according to claim 11 , wherein the compound of Formula Q is either dissolved in the polymeric matrix or dispersed in the polymeric matrix.
13. The pharmaceutical composition according to claim 12 , wherein the polymeric matrix comprises one or more polymers selected from the group consisting of poly(lactic acid), poly(glycolic acid), poly(citric acid), poly(malic acid), poly(beta-hydroxybutyric acid), lactic acid-glycolic acid copolymer, poly(lactide-co-glycolide), 2-hydroxybutyric acid-glycolic acid copolymer, poly(lactic acid)-poly(ethylene glycol) copolymer, poly(glycolic acid)-poly(ethylene glycol) copolymer, a poly(alkyl alpha-cyanoacrylate), a poly(alkylene oxalate), a poly(orthoester), a polycarbonate, a poly(orthocarbonate), a polyamino acid, a hyaluronic acid ester, a poly(aliphatic carboxylic acid), a copolyoxalate, a polycaprolactone, a polydioxanone, a poly(acetal), a poly(lactic acid-caprolactone), and a poly(glycolic acid-caprolactone).
14. The pharmaceutical composition according to claim 13 , wherein the polymeric matrix comprises a poly(D,L-lactide-co-glycolide) polymer.
15. The pharmaceutical composition according to claim 14 , wherein the polymeric matrix is a microspheric polymeric matrix comprising a biodegradable poly(D,L-lactide-co-glycolide) polymer.
16. The pharmaceutical composition according to claim 15 , wherein the pharmaceutical composition is formulated as a sustained-release and/or delayed release injectable composition.
17. The pharmaceutical composition according to claim 16 , wherein the viscosity enhancing agent is a sodium carboxymethylcellulose.